Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,804 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus - Type 1 Clear all
Active, not recruiting No phase listed Observational

Evaluating the InPen in Pediatric Type 1 Diabetes

NCT05515939
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
InPen Insulin Pen
Device
Lead sponsor
Wayne State University
Other
Eligibility
13 Years to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

NCT03084471
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
MEDI4736 (Durvalumab), MEDI4736 (Durvalumab) + Tremelimumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Santa Rosa, California • Washington D.C., District of Columbia • Tinley Park, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Not applicable Interventional

Sleep Intervention for Youth With Type 1 Diabetes

NCT01739712
View directory record Official record
Conditions
Diabetes
Interventions
Sleep extension, Fixed Sleep Duration
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
10 Years to 16 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Phase 1 Interventional Results available

Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.

NCT02206607
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-04937319 IR MST, PF-04937319 MR 1, PF-04937319 MR 2, PF-04937319 MR 3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
High Point, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 15, 2026, 8:13 AM EDT
Not listed Phase 1 Interventional

UVA Islet Cell Transplantation in Patients With Type I Diabetes

NCT00605592
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Pancreatic Islets of Langerhans Cell Transplant
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2009 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Phase 2 Interventional Results available

Islet Transplantation for Type 1 Diabetes

NCT00014911
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
Islet Transplantation, Sirolimus, Tacrolimus, Daclizumab, Sulfamethoxazole, Ganciclovir, Trimethoprim, Pentamidine
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 15, 2026, 8:13 AM EDT
Recruiting Not applicable Interventional

Glu-COACH: a Peer-mentoring Intervention to Reduce Disparities in Continuous Glucose Monitor (CGM) Use

NCT06171412
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Glu-COACH
Behavioral
Lead sponsor
Yale University
Other
Eligibility
13 Years to 21 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 15, 2026, 8:13 AM EDT
Withdrawn Not applicable Interventional

Supporting Treatment Adherence Needs in Diabetes

NCT01030471
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Family-based cognitive-behavioral treatment
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Phase 2 Interventional Results available

CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1

NCT01773707
View directory record Official record
Conditions
Abnormal Glucose Tolerance, Type 1 Diabetes
Interventions
CTLA4-Ig (Abatacept), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 45 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects

NCT03296800
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Probenecid, Rifampin, Verapamil
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Oct 15, 2026, 8:13 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

NCT03445533
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Ipilimumab, Tilsotolimod with Ipilimumab
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Phase 1 Interventional

Closed Loop System With Pramlintide Versus Exenatide

NCT01269008
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Medtronic ePID 2.0
Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 15, 2026, 8:13 AM EDT
Withdrawn No phase listed Observational

Hybrid Closed-Loop Insulin Delivery System in Type 1 Diabetes Candidates for a Living Donor Kidney Transplant

NCT03494010
View directory record Official record
Conditions
Diabetes, Type 1
Interventions
Observation
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Not applicable Interventional Results available

USS Virginia Closed-Loop for Overnight Control in Type 1 Diabetes

NCT02131766
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
DiAs, Sensor Augmented Pump Therapy
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Phase 1 Interventional

A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1

NCT00239148
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
E1 and G1
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
5
States / cities
Anniston, Alabama • Walnut Creek, California • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Phase 1 Interventional

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg

NCT01546558
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
30 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Oct 15, 2026, 8:13 AM EDT
Recruiting Phase 4 Interventional

Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

NCT06706284
View directory record Official record
Conditions
Spinal Cord Injuries, Type 2 Diabetes
Interventions
Semaglutide Injectable Product, Placebo
Drug · Other
Lead sponsor
Marzieh Salehi
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study of the Safety and Efficacy of Pancreatic Endocrine Cell Clusters Implanted Into the Omentum of Type 1 Diabetes Patients With Severe Hypoglycemia

NCT06651515
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
Allogeneic Pancreatic Endocrine Cell Clusters
Biological
Lead sponsor
Seraxis
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 15, 2026, 8:13 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Natural History of Autoimmune Diabetes and Its Complications

NCT00896610
View directory record Official record
Conditions
Diabetes Mellitus Type 1, Diabetes Mellitus Type 2
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years and older
Enrollment
356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Not applicable Interventional

Transition of Adolescents and Young Adults With Diabetes From Pediatric to Adult Care

NCT01109797
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Transition Social Behavioral Intervention, Diabetes Transition Clinic
Behavioral
Lead sponsor
University of Kansas
Other
Eligibility
16 Years to 29 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 15, 2026, 8:13 AM EDT
Terminated Phase 2 Interventional Results available

TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

NCT00451321
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Otelixizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
16
States / cities
Birmingham, Alabama • Walnut Creek, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Not applicable Interventional

Intervention Groups for Adolescents With Type 1 Diabetes Mellitus

NCT00622271
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Group Therapy
Behavioral
Lead sponsor
Children's Hospital and Health System Foundation, Wisconsin
Other
Eligibility
13 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Not applicable Interventional

Artificial Pancreas With Different Stress Assessments in the Outpatient Setting

NCT04142229
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
iAPS, Sensor-Augmented Pump
Device · Other
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Santa Barbara, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Not applicable Interventional Results available

Assessment of an Automatic Closed-loop Insulin Delivery System

NCT02366767
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Automatic closed-loop insulin delivery, Control
Device
Lead sponsor
Stanford University
Other
Eligibility
14 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
3
States / cities
Angelus Oaks, California • Mountain View, California • Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 15, 2026, 8:13 AM EDT